AdvanCell raised a $315 million Series D to support development of a lead-based prostate cancer radiopharmaceutical and to expand or shore up U.S. manufacturing capacity. The financing is framed as a continuation step for its Pluvicto challenger effort, with the company using funds to progress preclinical-to-clinical execution and improve scale-readiness for radioactive production. Radiopharmaceutical capital intensity is a growing barrier for scaling beyond early trials, and the round signals continued investor willingness to fund supply chain and process risk—not just early efficacy. For competitive positioning, manufacturing execution is likely to matter as much as trial design, given the operational constraints that shape patient access and dosing consistency.